Pemafibrate Effectively Reduced Triglycerides in Patients with a History of PCI or CABG

No abstract is available for this paper.

• Publication year

  2024

• Venue

  Journal of Coronary Artery Disease

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.7793/jcad.30.23-00013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study)

  2023cited by this paper
• Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.

  2022cited by this paper
• Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms

  2022cited by this paper
• Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism

  2021cited by this paper
• Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

  2018cited by this paper
• Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

  2018cited by this paper
• Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.

  2016cited by this paper
• The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.

  2016cited by this paper
• Mortality risk of triglyceride levels in patients with coronary artery disease

  2012cited by this paper

• No citing papers are available for this paper.